DK1019050T3 - Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet - Google Patents

Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet

Info

Publication number
DK1019050T3
DK1019050T3 DK98929232T DK98929232T DK1019050T3 DK 1019050 T3 DK1019050 T3 DK 1019050T3 DK 98929232 T DK98929232 T DK 98929232T DK 98929232 T DK98929232 T DK 98929232T DK 1019050 T3 DK1019050 T3 DK 1019050T3
Authority
DK
Denmark
Prior art keywords
treatment
antagonists
eye diseases
somatostatin receptor
somatostatin agonists
Prior art date
Application number
DK98929232T
Other languages
Danish (da)
English (en)
Inventor
Carsten Enggaard Stidsen
Michael Albert Crider
Michael Ankersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK1019050T3 publication Critical patent/DK1019050T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98929232T 1997-06-24 1998-06-22 Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet DK1019050T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK74797 1997-06-24
US5130097P 1997-06-30 1997-06-30
PCT/DK1998/000267 WO1998058646A1 (en) 1997-06-24 1998-06-22 Use of somatostatin agonists and antagonists for treating diseases related to the eye

Publications (1)

Publication Number Publication Date
DK1019050T3 true DK1019050T3 (da) 2002-07-08

Family

ID=26064570

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98929232T DK1019050T3 (da) 1997-06-24 1998-06-22 Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet

Country Status (10)

Country Link
EP (1) EP1019050B1 (ja)
JP (1) JP2002515912A (ja)
AT (1) ATE214604T1 (ja)
AU (1) AU7907198A (ja)
DE (1) DE69804332T2 (ja)
DK (1) DK1019050T3 (ja)
ES (1) ES2174447T3 (ja)
PT (1) PT1019050E (ja)
WO (1) WO1998058646A1 (ja)
ZA (1) ZA985410B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2246791A1 (en) * 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
EP1318994B1 (en) 2000-09-20 2008-02-27 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
US6518287B2 (en) 2000-09-20 2003-02-11 Schering Corporation Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
AU2001291040A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
CA2422729A1 (en) 2000-09-20 2002-06-06 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
KR20050059319A (ko) * 2002-10-31 2005-06-17 센주 세이야꾸 가부시키가이샤 각막 장해 치료제

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525793A (ja) * 1996-05-14 2001-12-11 ノボ ノルディスク アクティーゼルスカブ ソマトスタチンの作動因子及び拮抗因子
ZA979701B (en) * 1996-10-31 1998-05-21 Novo Nordisk As Novo Nordisk A Constrained somatostatin agonists and antagonists.Constrained somatostatin agonists and antagonists.

Also Published As

Publication number Publication date
ZA985410B (en) 1999-01-04
DE69804332D1 (de) 2002-04-25
JP2002515912A (ja) 2002-05-28
ES2174447T3 (es) 2002-11-01
EP1019050B1 (en) 2002-03-20
WO1998058646A1 (en) 1998-12-30
EP1019050A1 (en) 2000-07-19
DE69804332T2 (de) 2002-11-07
PT1019050E (pt) 2002-09-30
AU7907198A (en) 1999-01-04
ATE214604T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
Lin et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma
US20100130569A1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
JP4217832B2 (ja) 角結膜障害の治療剤
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
DK1239774T3 (da) Apparat til behandling af öjensygdomme
EP0743852B1 (en) Treatment of normotensive glaucoma with valsartan
WO2003047513A3 (en) Method for treating ocular hypertension
MXPA05010189A (es) Analogos de prostaglandina como antagonistas del receptor ep4.
NO20061701L (no) Tiazolderivater som cannabionoide reseptor modulatorer
TW200505402A (en) Ophthalmic drug delivery device
US20110130388A1 (en) Prophylactic or therapeutic agent for axial myopia
ATE487514T1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
DK1019050T3 (da) Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet
US10485786B2 (en) Pharmaceutical composition for preventing or treating macular degeneration
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
EA200501620A1 (ru) Лечение состояний, включающих амилоидные бляшки
US20180325913A1 (en) Rejection reaction suppressant
Kaneko et al. Additive intraocular pressure-lowering effects of ripasudil with glaucoma therapeutic agents in rabbits and monkeys
US20070161616A1 (en) Method for treating glaucoma IIB
CN113227086A (zh) 作为用于治疗神经视网膜疾病的视网膜前体细胞的生产的刺激剂的n-(4-(噁唑-5-基)苯基)色满-3-甲酰胺衍生物及相关化合物
KR20180044237A (ko) 안압 하강 증강제
EA200101180A1 (ru) Производные тио-оксиндола
CA3037116A1 (en) Methods for treating ocular disease using inhibitors of csf-1r
JP2008285478A (ja) アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
JP2003081874A (ja) α１受容体遮断薬を有効成分とする視神経保護剤